πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,196 results for β€œGE” Clear

  1. BG00012

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule completed

    1 trial

  2. BGB-3111

    BeiGene

    WaldenstrΓΆm's Macroglobulinemia

    phase 3 small molecule completed

    1 trial

  3. BGJ398

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  4. BHV-7000, Placebo for BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures

    phase 3 small molecule active

    1 trial

  5. BI 1015550, BI 1015550

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF)

    phase 3 small molecule active

    1 trial

  6. BI 1015550, Placebo matching BI 1015550, BI 1015550

    Boehringer Ingelheim

    Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

    phase 3 small molecule active

    1 trial

  7. BI 1015550, Placebo matching nerandomilast (BI 1015550)

    Boehringer Ingelheim

    Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

    phase 3 small molecule active

    1 trial

  8. BI 10773

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  9. BI 1291583

    Boehringer Ingelheim

    Bronchiectasis

    phase 3 small molecule active

    1 trial

  10. BI 201335

    Boehringer Ingelheim

    Hepatitis C, Chronic

    phase 3 small molecule completed

    1 trial

  11. BI 201335

    Boehringer Ingelheim

    Hepatitis C

    phase 3 small molecule completed

    1 trial

  12. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  13. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  14. BI 456906, BI 456906, BI 456906, BI 456906, Placebo matching products 1 to 7 (pre-filled syringe, filling volume: 0.5 mL), BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  15. BI 456906, Placebo, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity, Diabetes mellitus type II

    phase 3 small molecule active

    1 trial

  16. BI 695501

    Boehringer Ingelheim

    Arthritis, Rheumatoid

    phase 3 small molecule completed

    2 trials

  17. BI 764198

    Boehringer Ingelheim

    Focal Segmental Glomerulosclerosis

    phase 3 small molecule active

    1 trial

  18. BI 764198, Placebo matching BI 764198

    Boehringer Ingelheim

    Focal segmental glomerulosclerosis

    phase 3 small molecule active

    1 trial

  19. BI 907828, BI 907828, BI 907828

    Boehringer Ingelheim

    dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  20. BI 907828, BI 907828, Doxorubicin-Ebewe, 2 mg/ml, koncentrat do sporzΔ…dzania roztworu do infuzji, BI 907828

    Boehringer Ingelheim

    Advanced dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  21. BIIB019 (Daclizumab)

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule terminated

    1 trial

  22. BIIB059

    Biogen

    1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  23. BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

    Biogen

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  24. BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources